Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000824779 | SCV000271291 | likely pathogenic | Rare genetic deafness | 2015-05-14 | criteria provided, single submitter | clinical testing | The p.Thr4337Met variant in USH2A has been previously reported in 5 probands wit h Usher syndrome and 2 probands with retinitis pigmentosa (Aller 2006, McGee 201 0, Besnard 2014, Baux 2014, Lenassi 2015). Two of the probands with Usher syndr ome were compound heterozygotes with a second pathogenic or likely pathogenic va riant, and the two probands with retinitis pigmentosa were both compound heteroz ygous with a second pathogenic variant. This variant has not been identified in large population studies. Computational prediction tools and conservation analy sis do not provide strong support for or against an impact to the protein. In su mmary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic based on multiple reported occur rences with pathogenic USH2A variants in individuals with Usher syndrome. |
Labcorp Genetics |
RCV001043740 | SCV001207501 | pathogenic | not provided | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 4337 of the USH2A protein (p.Thr4337Met). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Usher syndrome or retinitis pigmentosa (PMID: 17085681, 24498627, 25324289, 25356976, 26654877, 26667666, 28944237, 29588463; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 143172). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001073283 | SCV001238819 | pathogenic | Retinal dystrophy | 2018-10-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001043740 | SCV001246242 | pathogenic | not provided | 2018-01-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV001043740 | SCV001762261 | pathogenic | not provided | 2021-06-17 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001043740 | SCV002021611 | likely pathogenic | not provided | 2021-08-26 | criteria provided, single submitter | clinical testing | |
Ophthalmic Genetics Group, |
RCV003324517 | SCV004030332 | pathogenic | Retinitis pigmentosa | 2023-07-24 | criteria provided, single submitter | research | Clinical significance based on ACMG v2.0 |
Genome- |
RCV000983996 | SCV004181915 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000983996 | SCV004208147 | pathogenic | Retinitis pigmentosa 39 | 2024-02-13 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV001073283 | SCV004707253 | pathogenic | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Department of Ophthalmology and Visual Sciences Kyoto University | RCV000132703 | SCV000172656 | pathogenic | Usher syndrome type 2A | no assertion criteria provided | not provided | Converted during submission to Pathogenic. | |
Counsyl | RCV000983996 | SCV000790257 | pathogenic | Retinitis pigmentosa 39 | 2017-03-24 | no assertion criteria provided | clinical testing |